BusinessPeregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With BavituximabBy Nasdaq OMXJan 6, 2016, 1:05 PM UTC
BusinessMidatech Pharma PLC (“Midatech”, the “Company” or the “Group”) Pre-Close Trading UpdateBy Nasdaq OMXJan 6, 2016, 7:00 AM UTC
BusinessNemucore Medical Innovations Announces Appointment of Dr. Michael V. Seiden to Its Board of Directors and Clinical Advisory BoardBy Nasdaq OMXDec 9, 2015, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXDec 7, 2015, 9:05 PM UTC
BusinessNemucore Medical Innovations Options Clinical-Stage Aurora Kinase Inhibitor GSK1070916 From Cancer Research Technology (CRT)By Nasdaq OMXDec 7, 2015, 1:10 PM UTC
BusinessNemucore Medical Innovations Completes Series A FinancingBy Nasdaq OMXDec 7, 2015, 1:05 PM UTC
BusinessPeregrine to Report Financial Results for Second Quarter of Fiscal Year 2016 After Market Close on December 10, 2015By Nasdaq OMXDec 3, 2015, 9:05 PM UTC
